Discovering Therapies for Neuromuscular Disorders

Deep Genomics to collaborate with Wave Life Sciences to discover novel therapies for genetic neuromuscular disorders

CAMBRIDGE, Mass. U.S.A. and TORONTO, Ontario, Canada, April 10, 2018 - Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., a biotechnology company that is building a new universe ...

Taking on Metabolic & Neurodegenerative Disorders

Deep Genomics to identify oligonucleotide candidates for treating genetically defined metabolic and neurodegenerative disorders

For the first time, machine learning will be used at every step of drug discovery to identify candidates for treating genetically defined metabolic and neurodegenerative disorders.

TORONTO, Ontario, Canada, March 26, 2018 - Deep Genomics, the genetic medicine company that has built a platform using machine ...

$13M Invested in AI Platform for Genetic Medicines

Equity investment by Khosla Ventures, True Ventures and Bloomberg Beta will be used to direct platform to drug discovery

AI platform to unlock new classes of anti-sense oligonucleotide therapies.

TORONTO, Ontario, Canada, September 25, 2017 - Deep Genomics, the AI driven genetic medicine company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied ...